A randomized phase III study on the effect of Thalidomide combined with Adriamycin, Dexamethasone (AD) and High Dose Melphalan in patients with multiple myeloma.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 450
研究概览
简要总结
Haematologica. 2008 Jan;93(1):124-7.
2 voorafgaande onderzoeken:
M.C. Minnema, I. Breitkreutz, J.J. Auwerda, B. van der Holt, F.W. Cremer, A.M. van Marion, P.H. Westveer, P. Sonneveld, H. Goldschmidt and H.M. Lokhorst. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia, 18(12), 2044-2046. 2004
H. Goldschmidt, P. Sonneveld, F.W. Cremer, B. van der Holt, P. Westveer, I. Breitkreutz, A. Benner, A. Glasmacher, I.G.D. Schmidt-Wolf, H. Martin, D. Hoelzer, A.D. Ho and H.M. Lokhorst. Joint HOVON-50/ GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Annals of Hematology, 82, 654-659. 2003
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with a confirmed diagnosis of multiple myeloma stage II or III according to the Salmon & Durie criteria;
- •2. Age 18-65 years inclusive;
排除标准
- •1. Known intolerance of Thalidomide;
- •2. Systemic AL amyloidosis;